T lineage cell |
hESC |
Feeder |
Serum‐containing Feeder: MEF, OP9, OP9‐DL1 |
43–61 days |
FLT3‐L, IL‐7, SCF |
In vitro TCR rearrangement and cytokine production assays |
11
|
T lineage cell |
hiPSC |
Feeder |
Serum‐containing Feeder: C3H10T1/2, OP9‐DLL1 |
16–45 days |
VEGF, SCF, FLT3L, IL‐7, IL‐15 |
In vitro cell cytotoxicity assays |
12
|
T lineage cell |
hiPSC |
Feeder |
Serum‐containing Feeder: MEF, OP9, OP9‐DLL1 |
~40 days |
FLT3‐L, IL‐7, SCF, IL‐2, anti‐human CD3, anti‐human CD28 |
In vitro TCR rearrangement and cytokine production assays |
13
|
T lineage cell |
hiPSC |
EB and DL4‐μbeads |
Serum‐free Feeder‐free |
~50 days |
BMP4, bFGF, SB431542, CHIR99021, IL‐6, IL‐11, VEGF, IGF‐1, SCF, EPO |
In vivo thymus engraftment assay |
14
|
T lineage cell |
hiPSC |
EB and immobilized DL4 protein |
Serum‐free Feeder‐free |
35–42 days |
VEGF, BMP4, bFGF, SCF, TPO, FLT3L, SB431542, CHIR99021, IL‐7, OKT3 |
In vitro and in vivo cell cytotoxicity assays |
15
|
T lineage cell |
hESC hiPSC |
Feeder and artificial thymic organoid (ATO) |
Serum‐free Feeder: MS5‐hDLL1/4 |
67 days |
Activin A, BMP4, VEGF, FGF, SCF, FLT3L, TPO, IL‐7, Ascorbic Acid |
In vitro TCR rearrangement and cell cytotoxicity assays |
16
|
NKT cell |
hiPSC |
Feeder |
Serum‐containing Feeder: C3H10T1/2, OP9‐DLL1 |
35 days |
VEGF, FLT3L, SCF, IL‐7, IL‐2, IL‐15 |
In vitro cell cytotoxicity assay |
17
|
NK cell |
hESC |
Feeder |
Serum‐containing Feeder: MEF, S17, AFT024 |
21–67 days |
IL‐15, IL‐3, IL‐7, SCF, FLT3L, |
In vitro cell cytotoxicity and cytokine production assays |
18
|
NK cell |
hESC hiPSC |
EB |
Serum‐free Feeder‐free |
39 days |
VEGF, BMP4, IL‐3, IL‐7, IL‐15, SCF, FLT3L |
In vitro specific killing assay |
19
|
NK cell |
hESC hiPSC |
EB |
Serum‐free Feeder‐free |
34 days |
VEGF, BMP4, IL‐3, IL‐7, IL‐15, SCF, FLT3L |
In vitro specific killing assay |
20
|
NK cell |
hESC hiPSC |
Feeder and organoid |
Serum‐free Feeder: OP9, OP9‐DLL1/DLL4 |
27 days |
BMP4, ACTIVIN A, bFGF, CHIR99021, PIK‐90, A‐83‐01, C59, SB431542, Hydrocortisone, SGR‐SM, FLT3L, TPO, SCF, EGF, VEGF, IGF‐1, Ascorbic Acid |
In vitro and in vivo cell cytotoxicity assays |
21
|
Macrophage |
hESC |
EB and Feeder |
Serum‐containing Feeder: S17 |
26–32 days |
GM‐CSF, M‐CSF |
In vitro phagocytosis, HIV infection, and cytokine production assays |
22
|
Macrophage |
hESC |
EB |
Serum‐containing Feeder: MEF |
~18 days for first harvest, multiple harvests |
M‐CSF, IL‐3 |
In vitro endocytosis, phagocytosis, cytokine production, and polarization assays |
23
|
Macrophage |
hESC hiPSC |
EB |
Serum‐free Feeder‐free |
~21 days for first harvest, multiple harvests |
BMP4, VEGF, SCF, M‐CSF, IL‐3 |
In vitro phagocytosis, HIV infection, and cytokine production assays |
24
|
Macrophage |
hiPSC |
EB |
Serum‐free Feeder: MEF |
~20 days for first harvest, multiple harvests |
M‐CSF, IL‐3 |
In vitro phagocytosis assay and in vivo bacterial infections |
25
,
26
|
Macrophage |
hESC hiPSC |
Monolayer |
Serum‐free Feeder‐free |
16–28 days |
BMP4, VEGF, SCF, bFGF, SCF, FL3, IL‐3, TPO, M‐CSF, GM‐CSF |
In vitro cytokine production, chemotaxis, and polarization assays |
27
|
Macrophage |
hiPSC |
Monolayer |
Serum‐free Feeder‐free |
15 days |
BMP4, Activin A, CHIR99021, SB431542, VEGF, bFGF, SCF, IL‐3, IL‐6, TPO, M‐CSF |
In vitro microfluidic flow adhesion, endocytosis, phagocytosis, polarization, and cytokine production and chemokines assays |
28
,
29
|
Dendritic cell |
hESC |
Feeder |
Serum‐containing Feeder: OP9‐DL1 |
24–29 days |
GM‐CSF, IL‐4 |
In vitro antigen presentation assay |
30
|
Dendritic cell |
hESC |
EB |
Serum‐free Feeder‐free |
17–25 days |
BMP4, VEGF, SCF, GM‐CSF, IL‐4 |
In vitro phagocytosis and antigen presentation assays |
31
|
Dendritic cell |
hiPSC |
Feeder |
Serum‐free Feeder‐free |
28 days |
GM‐CSF, FLT3L, SCF, VEGF, BMP4 |
In vitro phagocytosis, antigen presentation, and cytokine production assays |
32
|
B cell |
hiPSC |
Feeder |
Serum‐containing Feeder: OP9, MS5 |
21–42 days |
IL‐3, IL‐7, SCF, FLT3L |
In vitro VDJ rearrangement assay |
33
|
B cell |
hESC hiPSC |
Feeder |
Serum‐containing Feeder: OP9, MS5 |
39 days |
bFGF, IL‐3, FLT3L, SCF, IL‐7 |
N/A |
34
|
Microglia |
hESC hiPSC |
EB |
Serum‐free Feeder: MEF |
74 days |
M‐CSF, IL‐34 |
In vitro cytokine production assay |
35
|
Microglia |
hiPSC |
Monolayer |
Serum‐free Feeder‐free |
26 days |
BMP4, VEGF, CHIR99021, FGF2, SCF, DKK1, IL‐3, IL‐6, M‐CSF |
In vitro phagocytosis and cytokine production assays |
36
|